Coherus Oncology, Inc. (CHRS) News
Track canonical SquawkNews coverage tagged to CHRS, Coherus Oncology, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 12 indexed stories across 6 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Coherus Oncology Initiates Process To Sell Legacy Biosim Assets
Coherus Oncology Inc NASDAQ:CHRS
NEWS | Sep 23, 2026, 02:16 PM UTC
L
Coherus Oncology, Inc. (CHRS) Hires Oppenheimer to Sell Legacy Biosim Assets; CVRs in Place
Coherus Oncology retained Oppenheimer to market and sell its legacy biosimilar assets. Holders of CVRs, to be distributed to stockholders of record on Sept. 30, 2026, will receive their pro rata share of any net proceeds
NEWS | Sep 23, 2026, 01:32 PM UTC
L
Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
Oppenheimer Initiates a Robust Process with Global Reach for the Benefit of Shareholders -REDWOOD CITY, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. NASDAQ:CHRS today announced that it has initiated
NEWS | Sep 23, 2026, 01:32 PM UTC
L
CHRS - Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
CHRS - Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
NEWS | Sep 23, 2026, 01:30 PM UTC
L
CHRS: Innovative oncology focus drives pipeline progress, with key data readouts expected by year-end
The company has fully transitioned to innovative oncology, with LOQTORZI driving revenue growth and funding a robust pipeline. Key assets tagmokitug and casdozokitug are advancing in trials, with major data updates expec
EARNINGS | Sep 15, 2026, 05:00 PM UTC
L
CHRS: Strategic oncology focus drives revenue growth and key clinical milestones, with major data readouts ahead
A completed pivot to innovative oncology has positioned the company as both a commercial and clinical stage player, with LOQTORZI driving revenue and funding pipeline development. Key data readouts for tagmokitug and cas
EARNINGS | Sep 15, 2026, 04:32 PM UTC
L
CHRS: Pipeline advances and strong LOQTORZI sales position for growth, with major data readouts ahead
The conference highlighted a robust oncology pipeline focused on immune resistance, with LOQTORZI driving commercial growth and tagmokitug and casdozokitug advancing in multiple cancer indications. Key data readouts and
EARNINGS | Sep 15, 2026, 01:24 PM UTC
L
CHRS: Pipeline advances and commercial execution position for growth, with major data readouts ahead
The conference highlighted a robust oncology pipeline targeting immune resistance, with LOQTORZI driving commercial growth and tagmokitug and casdozokitug advancing in multiple indications. Key data readouts are expected
EARNINGS | Sep 15, 2026, 12:48 PM UTC
L
Coherus Oncology files $50M at-the-market sales agreement
Coherus Oncology filed a $50M at-the-market sales agreement with Leerink Partners.
EQUITY | Aug 28, 2026, 09:14 PM UTC
L
Coherus Oncology unveils CVR dividend, starts biosimilar asset sale
Coherus Oncology said it will distribute a special dividend of contingent value rights to common stockholders of record on September 30, 2026 and immediately commence a sale process for its legacy biosimilar assets.
EARNINGS | Aug 17, 2026, 09:37 PM UTC
L
CHRS - Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update
CHRS - Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update
EARNINGS | Aug 05, 2026, 08:28 PM UTC